ArticleThe Journal of biological chemistry2025
TET2 has endothelial-specific roles in interferon responses that are dysregulated by hyperglycemia in vitro and in vivo.
Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated DNA methylation in the endothelium is associated with the development of cardiovascular disease. Ten-eleven translocation 2 (TET2), a DNA demethylase, plays a regulatory role in endothelial function. Loss of endothelial-expressed TET2 correlates with atherosclerosis progression in vivo and alters vasoactive signaling in vitro. Hyperglycemia acts to downregulate TET2 stability and activity in endothelial cells, but the relevance of this to endothelial dysfunction in diabetes remains unclear. Here, we explore the transcriptional and functional consequences of endothelial-specific TET2 loss in vivo and assess the role of DNA methylation in TET2-dependent transcriptional regulation. Ex vivo aortic responses to acetylcholine and phenylephrine were equivalent between wild-type and endothelial-specific TET2 knockout (TET2KO) mice. RNA sequencing of endothelial-enriched lung cells from TET2KO mice revealed significant dysregulation of interferon signaling. In cultured endothelial cells, qPCR, hydroxymethylated-DNA immunoprecipitation sequencing, and nanopore sequencing showed that IFITM1 and ISG15-classical interferon-responsive genes-were negatively regulated by TET2 independent of DNA demethylation. Conversely, the IFNγ-inducible chemokines CXCL9 and CXCL10 were positively regulated by TET2 in a mechanism involving catalytic demethylation, as evidenced by increased 5hmC and decreased 5 mC at an enhancer region. Strikingly, approximately 70% of transcriptional changes observed in TET2KO endothelium were mirrored in diabetic mouse endothelium. Pathway analysis highlighted dysregulation of interferon signaling and altered glycosaminoglycan metabolism as the most significant biological consequences. In summary, endothelial TET2 loss leads to transcriptional dysregulation of interferon-regulated genes, partly through altered DNA methylation. This may have relevance to the susceptibility of diabetics to recurrent viral infections and endothelial dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.